Hisamitsu Pharmaceutical Co., Inc.
HTSUF · OTC
2/28/2025 | 2/28/2024 | 2/28/2023 | 2/28/2022 | |
|---|---|---|---|---|
| Market Cap | $272,295,024 | $298,806,092 | $332,404,427 | $326,946,819 |
| - Cash | $114,518,000 | $112,459,000 | $122,154,000 | $129,290,000 |
| + Debt | $3,856,000 | $2,100,000 | $2,295,000 | $2,460,000 |
| Enterprise Value | $161,633,024 | $188,447,092 | $212,545,427 | $200,116,819 |
| Revenue | $156,006,000 | $141,706,000 | $128,330,000 | $120,193,000 |
| % Growth | 10.1% | 10.4% | 6.8% | – |
| Gross Profit | $91,196,000 | $78,971,000 | $72,700,000 | $70,067,000 |
| % Margin | 58.5% | 55.7% | 56.7% | 58.3% |
| EBITDA | $35,045,000 | $24,376,000 | $16,553,000 | $17,297,000 |
| % Margin | 22.5% | 17.2% | 12.9% | 14.4% |
| Net Income | $21,758,000 | $13,969,000 | $11,742,000 | $9,658,000 |
| % Margin | 13.9% | 9.9% | 9.1% | 8% |
| EPS Diluted | 295.15 | 181.42 | 147.87 | 118.84 |
| % Growth | 62.7% | 22.7% | 24.4% | – |
| Operating Cash Flow | $18,765,000 | $18,188,000 | $12,727,000 | $19,199,000 |
| Capital Expenditures | -$13,774,000 | -$13,036,000 | -$7,908,000 | -$4,193,000 |
| Free Cash Flow | $4,991,000 | $5,152,000 | $4,819,000 | $15,006,000 |